Patient interviews with people who have experienced HCV reinfection v3
Research type
Research Study
Full title
Patient interviews with people who have experienced hepatitis C virus reinfection
IRAS ID
331334
Contact name
Avelie Stuart
Contact email
Sponsor organisation
UKHSA
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
With the successful treatment of hepatitis C virus (HCV) using direct-acting antivirals (DAAs), HCV reinfection may pose a more significant issue compared to previous eras of treatment. HCV reinfection needs to be further investigated to aid England’s ability to achieve HCV elimination by the year 2030. In this study we will explore HCV reinfection by conducting qualitative interviews with patients who have experienced HCV reinfection. The aim of the study is to understand individuals’ knowledge of HCV treatment and risks of reinfection, their experiences of being offered ongoing testing and treatment and whether these offers were appropriate to their needs, and any barriers they have experienced in being reengaged in care or accessing harm reduction facilities. Support is requested for the flow of patient name and contact details from NHS sites to the UK Health Security Agency (UKHSA). Sites will identify potential participants from their treatment databases and phone them to gain permission for the UKHSA research team to make contact. Participants who agree will then be invited to have a 1 hour telephone interview with a UKHSA researcher.
REC name
London - Stanmore Research Ethics Committee
REC reference
23/LO/0753
Date of REC Opinion
19 Sep 2023
REC opinion
Favourable Opinion